Stock Analysis on Net
Stock Analysis on Net

AbbVie Inc. (NYSE:ABBV)

Common Stock Valuation Ratios (Price Multiples)
Quarterly Data

Microsoft Excel LibreOffice Calc

Historical Valuation Ratios (Summary)

AbbVie Inc., historical price multiples (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
Price to earnings (P/E) 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82 37.29 23.42 21.71 20.60 17.29 22.09 24.91 35.47 22.56 17.16 16.90 16.54
Price to operating profit (P/OP) 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82 18.43 13.53 17.93 18.35 12.32 14.01 15.78 19.63 14.77 11.57 11.19 10.49
Price to sales (P/S) 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22 3.69 2.96 3.56 3.58 4.06 4.60 5.37 6.67 5.50 4.25 4.07 3.84
Price to book value (P/BV) 15.20 16.23 14.91 14.18 10.93 11.31 44.74 36.95 22.43 18.89 21.33 21.24 14.80 19.21 21.77

Based on: 10-Q (filing date: 2021-11-02), 10-Q (filing date: 2021-08-02), 10-Q (filing date: 2021-05-07), 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. AbbVie Inc.’s P/E ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. AbbVie Inc.’s P/OP ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. AbbVie Inc.’s P/S ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. AbbVie Inc.’s P/BV ratio increased from Q1 2021 to Q2 2021 but then slightly decreased from Q2 2021 to Q3 2021 not reaching Q1 2021 level.

Price to Earnings (P/E)

AbbVie Inc., historical P/E calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177 1,475,083,514 1,504,216,327 1,514,272,698 1,586,879,451 1,587,972,655 1,596,429,740 1,594,094,698 1,591,540,513 1,593,920,285 1,625,099,012 1,628,542,359 1,617,358,607
Selected Financial Data (US$)
Net earnings (loss) attributable to AbbVie Inc. (in millions) 3,179  766  3,553  36  2,308  (738) 3,010  2,801  1,884  741  2,456  (1,826) 2,747  1,983  2,783  52  1,631  1,915  1,711  1,391  1,598  1,610  1,354 
Earnings per share (EPS)2 4.26 3.77 2.92 2.61 4.18 3.94 5.71 5.33 2.20 2.79 3.63 3.86 5.03 4.26 4.02 3.34 4.16 4.15 3.96 3.73 0.00 0.00 0.00
Share price1, 3 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71 79.41 86.96 94.06 100.17 118.60 93.96 71.22 66.99 61.77 58.91 66.54 62.51
Valuation Ratio
P/E ratio4 27.34 30.62 39.63 40.17 22.60 23.92 14.70 17.82 37.29 23.42 21.71 20.60 17.29 22.09 24.91 35.47 22.56 17.16 16.90 16.54
Benchmarks
P/E Ratio, Competitors5
Amgen Inc. 21.91 22.56 19.20 18.82 17.25 19.97 17.70 17.07 15.53 14.06 13.30 14.01 55.79 52.69 52.13 64.06 15.67 15.70 15.16 16.03
Eli Lilly & Co. 40.07 40.34 28.77 31.95 22.54 25.59 26.56 16.19 13.31 13.84 18.38 39.13 249.24 79.88 41.51 37.39 41.29 32.39
Gilead Sciences Inc. 11.44 16.83 277.25 641.48 59.19 19.58 16.45 30.72 13.61 14.26 15.26 57.34 45.72 24.66 22.75 8.24 7.85 6.92 6.83
Illumina Inc. 70.41 94.98 93.98 109.92 66.98 74.93 47.73 43.43 43.91 46.92 54.25 52.00 62.22 73.58 59.94 44.63 38.26 38.75 36.92 52.01
Johnson & Johnson 23.98 25.51 28.35 28.92 22.51 25.68 23.06 25.99 24.03 21.50 25.68 23.74 243.48 256.64 271.47 268.10 23.75 21.91 20.12 20.08
Merck & Co. Inc. 28.65 34.23 28.00 26.72 17.67 19.70 19.18 20.60 22.67 23.07 23.97 33.46 56.97 132.14 96.71 61.63 53.20 33.41 39.83 46.14
Moderna Inc. 16.31 48.08 107.74
Pfizer Inc. 14.03 20.05 20.15 19.62 25.36 14.99 13.04 11.63 12.60 16.12 19.69 21.58 10.64 10.66 9.43 9.99 21.39 23.88 27.02 28.10
Regeneron Pharmaceuticals Inc. 9.96 10.38 13.27 15.09 19.91 22.27 28.35 19.86 17.03 15.94 14.56 18.17 21.53 26.96 22.09 28.99 34.90 43.35 47.93 42.64
Thermo Fisher Scientific Inc. 29.43 24.63 23.23 27.89 38.43 44.19 35.50 33.36 33.89 31.08 35.11 35.19 36.71 39.27 37.52 37.66 33.39 30.36 30.83 30.45
Zoetis Inc. 51.98 50.61 44.83 48.25 48.84 47.41 37.05 45.89 39.46 42.08 35.57 28.68 38.90 39.51 39.53 44.09 35.00 33.42 33.79 31.63

Based on: 10-Q (filing date: 2021-11-02), 10-Q (filing date: 2021-08-02), 10-Q (filing date: 2021-05-07), 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Data adjusted for splits and stock dividends.

2 Q3 2021 Calculation
EPS = (Net earnings (loss) attributable to AbbVie Inc.Q3 2021 + Net earnings (loss) attributable to AbbVie Inc.Q2 2021 + Net earnings (loss) attributable to AbbVie Inc.Q1 2021 + Net earnings (loss) attributable to AbbVie Inc.Q4 2020) ÷ No. shares of common stock outstanding
= (3,179,000,000 + 766,000,000 + 3,553,000,000 + 36,000,000) ÷ 1,767,880,465 = 4.26

3 Closing price as at the filing date of AbbVie Inc.’s Quarterly or Annual Report.

4 Q3 2021 Calculation
P/E ratio = Share price ÷ EPS
= 116.53 ÷ 4.26 = 27.34

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/E ratio The P/E ratio tells analyst how much an investor in common stock pays per dollar of current earnings. AbbVie Inc.’s P/E ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.

Price to Operating Profit (P/OP)

AbbVie Inc., historical P/OP calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177 1,475,083,514 1,504,216,327 1,514,272,698 1,586,879,451 1,587,972,655 1,596,429,740 1,594,094,698 1,591,540,513 1,593,920,285 1,625,099,012 1,628,542,359 1,617,358,607
Selected Financial Data (US$)
Operating earnings (in millions) 4,306  4,441  4,103  3,753  3,255  752  3,603  3,956  2,617  3,400  3,010  (2,441) 3,159  2,762  2,903  1,794  2,705  2,674  2,419  2,358  2,361  2,387  2,278 
Operating profit per share2 9.39 8.80 6.72 6.43 6.55 6.19 9.19 8.78 4.45 4.82 4.39 4.33 7.06 6.71 6.35 6.04 6.36 6.16 5.98 5.89 0.00 0.00 0.00
Share price1, 3 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71 79.41 86.96 94.06 100.17 118.60 93.96 71.22 66.99 61.77 58.91 66.54 62.51
Valuation Ratio
P/OP ratio4 12.41 13.12 17.23 16.32 14.42 15.23 9.13 10.82 18.43 13.53 17.93 18.35 12.32 14.01 15.78 19.63 14.77 11.57 11.19 10.49
Benchmarks
P/OP Ratio, Competitors5
Amgen Inc. 16.73 17.48 15.26 14.96 13.82 15.84 14.22 13.84 12.52 11.35 10.73 11.46 12.13 12.16 11.45 12.71 12.55 12.46 11.99 12.64
Eli Lilly & Co. 37.21 42.01 31.17 32.66 22.98 25.58 24.82 27.08 23.37 23.99 38.43 33.99 37.45 47.62 25.86 39.61 33.07 29.23 32.37 25.63
Gilead Sciences Inc. 7.27 8.88 18.31 19.38 29.86 21.83 20.66 19.07 9.61 10.14 10.15 9.74 9.58 6.83 7.45 6.02 5.82 5.22 5.23
Illumina Inc. 108.07 101.39 124.33 59.77 60.31 46.36 44.17 46.74 51.96 53.12 48.64 46.46 55.70 44.02 53.47 57.62 58.10 52.79 40.99
Johnson & Johnson 18.99 20.14 21.12 21.84 19.46 19.66 18.67 19.83 17.23 19.08 20.36 18.34 20.42 18.93 18.18 18.94 18.71 17.29 15.95 16.09
Merck & Co. Inc. 30.71 38.03 30.14 23.89 16.00 17.23 15.88 17.47 17.97 18.21 19.17 25.08 25.60 34.95 27.63 22.58 38.37 25.21 30.01 33.62
Moderna Inc. 15.13 44.01 101.69
Pfizer Inc. 16.38 19.84 22.88 23.12 22.27 22.17 17.42 14.36 14.64 13.82 15.62 17.19 18.14 17.36 15.05 15.62 16.20 16.11 16.34 16.88
Regeneron Pharmaceuticals Inc. 9.32 9.65 13.32 14.82 20.36 23.98 26.60 19.01 16.21 15.41 14.44 17.53 16.43 18.75 14.23 16.71 23.63 29.60 32.24 28.70
Thermo Fisher Scientific Inc. 23.87 19.77 18.53 22.81 31.49 36.59 28.44 26.84 26.99 24.59 28.45 27.33 26.24 28.33 26.99 28.24 28.12 25.79 26.21 25.13
Zoetis Inc. 38.47 36.90 32.33 35.22 36.65 36.24 28.78 35.00 30.23 32.11 27.78 22.59 23.98 23.28 21.51 22.33 21.75 20.64 20.42 18.65

Based on: 10-Q (filing date: 2021-11-02), 10-Q (filing date: 2021-08-02), 10-Q (filing date: 2021-05-07), 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Data adjusted for splits and stock dividends.

2 Q3 2021 Calculation
Operating profit per share = (Operating earningsQ3 2021 + Operating earningsQ2 2021 + Operating earningsQ1 2021 + Operating earningsQ4 2020) ÷ No. shares of common stock outstanding
= (4,306,000,000 + 4,441,000,000 + 4,103,000,000 + 3,753,000,000) ÷ 1,767,880,465 = 9.39

3 Closing price as at the filing date of AbbVie Inc.’s Quarterly or Annual Report.

4 Q3 2021 Calculation
P/OP ratio = Share price ÷ Operating profit per share
= 116.53 ÷ 9.39 = 12.41

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/OP ratio Because P/E ratio is calculated using net income, the ratio can be sensitive to nonrecurring earnings and capital structure, analysts may use price to operating profit. AbbVie Inc.’s P/OP ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.

Price to Sales (P/S)

AbbVie Inc., historical P/S calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177 1,475,083,514 1,504,216,327 1,514,272,698 1,586,879,451 1,587,972,655 1,596,429,740 1,594,094,698 1,591,540,513 1,593,920,285 1,625,099,012 1,628,542,359 1,617,358,607
Selected Financial Data (US$)
Net revenues (in millions) 14,342  13,959  13,010  13,858  12,902  10,425  8,619  8,704  8,479  8,255  7,828  8,305  8,236  8,278  7,934  7,739  6,995  6,944  6,538  6,796  6,432  6,452  5,958 
Sales per share2 31.21 30.40 28.42 25.94 23.02 20.53 23.06 22.49 22.23 22.07 22.08 22.20 21.40 20.44 18.66 17.77 17.08 16.76 16.47 16.08 0.00 0.00 0.00
Share price1, 3 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71 79.41 86.96 94.06 100.17 118.60 93.96 71.22 66.99 61.77 58.91 66.54 62.51
Valuation Ratio
P/S ratio4 3.73 3.80 4.07 4.05 4.10 4.59 3.64 4.22 3.69 2.96 3.56 3.58 4.06 4.60 5.37 6.67 5.50 4.25 4.07 3.84
Benchmarks
P/S Ratio, Competitors5
Amgen Inc. 5.04 5.37 5.68 5.64 5.33 6.30 5.96 6.03 5.61 5.00 4.78 5.22 5.56 5.65 5.27 5.82 5.85 5.85 5.48 5.65
Eli Lilly & Co. 8.62 9.16 6.88 8.06 5.41 6.26 6.36 6.03 4.67 4.67 4.80 5.15 4.62 4.34 3.85 3.71 4.11 4.16 4.18 4.18
Gilead Sciences Inc. 3.11 3.30 3.31 3.24 3.29 3.95 4.34 4.00 3.76 3.69 3.84 3.84 4.17 4.43 3.52 4.10 3.54 3.42 3.05 3.08
Illumina Inc. 14.90 18.39 17.05 22.26 13.20 15.50 12.64 12.28 12.35 12.92 13.59 12.89 13.12 15.36 11.58 11.77 11.53 11.65 11.27 10.03
Johnson & Johnson 4.69 5.08 5.09 5.15 4.73 4.84 4.78 4.79 4.16 4.32 4.62 4.45 4.61 4.36 4.29 4.56 5.06 4.93 4.60 4.62
Merck & Co. Inc. 4.32 4.05 4.23 3.93 4.30 4.38 4.05 4.33 4.59 4.87 4.67 4.92 4.57 4.29 3.75 3.68 3.80 4.25 4.34 4.54
Moderna Inc. 10.53 27.41 33.34 309.64
Pfizer Inc. 4.03 4.77 4.84 4.50 4.71 4.69 4.21 3.66 3.85 3.80 4.20 4.49 4.75 4.51 3.89 4.05 4.00 3.80 3.75 3.84
Regeneron Pharmaceuticals Inc. 5.14 5.20 5.78 6.24 7.62 8.31 8.10 5.34 4.79 4.56 5.11 6.62 6.08 6.92 5.20 5.92 8.09 9.56 9.27 7.86
Thermo Fisher Scientific Inc. 6.45 5.54 5.13 5.52 6.58 6.24 5.08 4.83 4.83 4.43 4.52 4.24 3.95 4.07 3.84 4.01 3.92 3.58 3.57 3.37
Zoetis Inc. 13.53 13.03 11.34 11.84 12.42 12.09 9.42 11.00 9.37 9.57 8.35 7.03 7.92 7.88 7.10 7.18 6.40 5.85 5.83 5.31

Based on: 10-Q (filing date: 2021-11-02), 10-Q (filing date: 2021-08-02), 10-Q (filing date: 2021-05-07), 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Data adjusted for splits and stock dividends.

2 Q3 2021 Calculation
Sales per share = (Net revenuesQ3 2021 + Net revenuesQ2 2021 + Net revenuesQ1 2021 + Net revenuesQ4 2020) ÷ No. shares of common stock outstanding
= (14,342,000,000 + 13,959,000,000 + 13,010,000,000 + 13,858,000,000) ÷ 1,767,880,465 = 31.21

3 Closing price as at the filing date of AbbVie Inc.’s Quarterly or Annual Report.

4 Q3 2021 Calculation
P/S ratio = Share price ÷ Sales per share
= 116.53 ÷ 31.21 = 3.73

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/S ratio An rationale for the P/S ratio is that sales, as the top line in an income statement, are generally less subject to distortion or manipulation than other fundamentals such as EPS or book value. Sales are also more stable than earnings and never negative. AbbVie Inc.’s P/S ratio decreased from Q1 2021 to Q2 2021 and from Q2 2021 to Q3 2021.

Price to Book Value (P/BV)

AbbVie Inc., historical P/BV calculation (quarterly data)

Microsoft Excel LibreOffice Calc
Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016
No. shares of common stock outstanding1 1,767,880,465 1,767,175,532 1,766,222,336 1,765,881,690 1,765,473,923 1,764,833,246 1,476,742,215 1,479,156,683 1,478,821,109 1,478,483,838 1,478,332,177 1,475,083,514 1,504,216,327 1,514,272,698 1,586,879,451 1,587,972,655 1,596,429,740 1,594,094,698 1,591,540,513 1,593,920,285 1,625,099,012 1,628,542,359 1,617,358,607
Selected Financial Data (US$)
Stockholders’ equity (deficit) (in millions) 13,550  12,569  13,710  13,076  15,270  14,708  (7,415) (8,172) (8,226) (8,566) (7,826) (8,446) (2,921) (3,375) 3,553  5,097  6,687  6,009  4,998  4,636  6,469  5,640  4,643 
Book value per share (BVPS)2 7.66 7.11 7.76 7.40 8.65 8.33 -5.02 -5.52 -5.56 -5.79 -5.29 -5.73 -1.94 -2.23 2.24 3.21 4.19 3.77 3.14 2.91 3.98 3.46 2.87
Share price1, 3 116.53 115.45 115.75 105.01 94.50 94.29 83.96 94.96 82.08 65.23 78.71 79.41 86.96 94.06 100.17 118.60 93.96 71.22 66.99 61.77 58.91 66.54 62.51
Valuation Ratio
P/BV ratio4 15.20 16.23 14.91 14.18 10.93 11.31 44.74 36.95 22.43 18.89 21.33 21.24 14.80 19.21 21.77
Benchmarks
P/BV Ratio, Competitors5
Amgen Inc. 14.95 15.72 14.57 14.53 11.57 13.67 14.33 13.84 11.47 10.37 9.92 9.41 8.56 8.35 7.41 5.02 3.98 4.05 3.91 4.14 3.51 4.27 4.16
Eli Lilly & Co. 30.85 38.00 25.41 35.07 26.02 35.12 47.73 51.67 31.28 39.03 46.37 12.87 8.58 8.96 6.18 7.33 6.20 6.49 6.43 6.33 5.28 6.25 5.55
Gilead Sciences Inc. 3.94 4.41 4.40 4.33 4.30 4.79 4.40 3.93 4.02 3.58 3.83 3.89 3.98 4.66 4.15 5.15 3.85 4.23 4.28 4.88 5.78 6.83 8.42
Illumina Inc. 6.02 14.08 12.03 15.36 9.09 11.38 9.70 9.43 9.62 10.16 11.58 11.43 12.15 14.64 11.30 11.79 10.48 10.67 10.71 10.95 9.03 11.90 10.48
Johnson & Johnson 6.10 6.51 6.51 6.72 5.93 6.19 6.46 6.61 5.84 5.78 6.39 6.08 5.81 5.60 5.34 5.79 5.08 4.98 4.72 4.72 4.30 4.68 4.34
Merck & Co. Inc. 5.76 5.73 7.30 7.46 6.97 7.47 7.43 7.83 7.87 7.82 7.31 7.79 5.88 5.44 4.54 4.30 3.96 4.31 4.35 4.51 3.78 4.01 3.42
Moderna Inc. 11.37 25.06 16.79 24.16 9.67 9.88 12.03 8.21 4.29 3.25 5.29
Pfizer Inc. 3.69 3.78 3.27 2.98 3.10 3.31 3.16 3.00 3.14 3.42 3.84 3.80 3.55 3.44 2.80 2.98 3.45 3.41 3.37 3.40 3.21 3.40 3.19
Regeneron Pharmaceuticals Inc. 4.04 4.26 4.44 4.81 6.21 7.34 5.33 3.79 3.48 3.38 3.74 5.07 4.92 5.97 4.80 5.66 7.37 9.07 9.49 8.58 8.02 11.19 10.54
Thermo Fisher Scientific Inc. 6.51 5.75 5.25 5.15 5.89 5.48 4.56 4.16 4.15 3.83 4.02 3.75 3.51 3.55 3.24 3.30 3.14 3.07 3.07 2.86 2.67 2.92 2.76
Zoetis Inc. 22.02 22.21 19.45 20.97 22.55 25.71 21.68 25.42 21.53 24.00 21.31 18.74 21.38 22.36 19.72 21.52 16.49 17.11 17.96 17.46 15.25 18.64 20.16

Based on: 10-Q (filing date: 2021-11-02), 10-Q (filing date: 2021-08-02), 10-Q (filing date: 2021-05-07), 10-K (filing date: 2021-02-19), 10-Q (filing date: 2020-11-04), 10-Q (filing date: 2020-08-04), 10-Q (filing date: 2020-05-08), 10-K (filing date: 2020-02-21), 10-Q (filing date: 2019-11-06), 10-Q (filing date: 2019-08-05), 10-Q (filing date: 2019-05-03), 10-K (filing date: 2019-02-27), 10-Q (filing date: 2018-11-07), 10-Q (filing date: 2018-08-07), 10-Q (filing date: 2018-05-04), 10-K (filing date: 2018-02-16), 10-Q (filing date: 2017-11-07), 10-Q (filing date: 2017-08-07), 10-Q (filing date: 2017-05-05), 10-K (filing date: 2017-02-17), 10-Q (filing date: 2016-11-07), 10-Q (filing date: 2016-08-05), 10-Q (filing date: 2016-05-06).

1 Data adjusted for splits and stock dividends.

2 Q3 2021 Calculation
BVPS = Stockholders’ equity (deficit) ÷ No. shares of common stock outstanding
= 13,550,000,000 ÷ 1,767,880,465 = 7.66

3 Closing price as at the filing date of AbbVie Inc.’s Quarterly or Annual Report.

4 Q3 2021 Calculation
P/BV ratio = Share price ÷ BVPS
= 116.53 ÷ 7.66 = 15.20

5 Click competitor name to see calculations.

Valuation ratio Description The company
P/BV ratio The P/BV ratio is interpreted as an indicator of market judgment about the relationship between a company’s required rate of return and its actual rate of return. AbbVie Inc.’s P/BV ratio increased from Q1 2021 to Q2 2021 but then slightly decreased from Q2 2021 to Q3 2021 not reaching Q1 2021 level.